Pharmacology and clinical experience with saquinavir

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 2, 2001, Pages 303-315

  Kravcik, S ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antiretroviral therapy; HIV; Protease inhibitor; Saquinavir

Indexed keywords

ABACAVIR; AMPRENAVIR; ASTEMIZOLE; CARBAMAZEPINE; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450 3A4; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ERGOT DERIVATIVE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ASTHENIA; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG MARKETING; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DYSPEPSIA; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOLOGY; LIPODYSTROPHY; METABOLIC DISORDER; NAUSEA; NEUTROPENIA; PARESTHESIA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

BIOLOGICAL AVAILABILITY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR; RANDOMIZED CONTROLLED TRIALS; RITONAVIR; SAQUINAVIR; VIRUS REPLICATION;

EID: 0035022248     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.2.303     Document Type: Article

References (80)

1. Course of HIV-I infection in a cohort of homosexual and bisexual men: An 11 year follow-up study
2. Clinical manifestations of AIDS in the era of Pheumocystis prophylaxis
3. The causes of death of HIV-infected persons in Ottawa, 1984 - 1995
4. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
5. HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifespan and viral generation time
6. Variation in plasma RNA levels, CD4 cell counts and p24 antigen levels in clinically stable men with human immunodeficiency virus infection
7. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response
8. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 at the nadir
9. Poor penetration of the male genital tract by HIV-1 protease inhibitors
10. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir
11. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein
12. Rational design of peptide-based HIV proteinase inhibitors
13. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase
14. Reversible inhibition of acute and chronic HIV-1 infection by an inhibition of virus protease
15. Human immunodeficiency virus Type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-α A against zidovudine-sensitive or -resistant HIV-1 in vitro
16. Safety and activity of saquinavir in HIV infection
17. A Phase I-II dose ranging study of the safety and activity of Ro 31-8959 (HIV-proteinase inhibitor) in previously zidovudine (ZDV) treated HIV-infected individuals
18. Exposure-response relationships for saquinavir, zidovudine and zalcitabine in combination therapy
19. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients
20. Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir
21. Fortovase (saquinavir; SQV) soft gel capsule (SGC) in combination with AZT and 3TC in antiretroviral-naive HIV-1 infected patients
22. Safety of saquinavir soft gelatin capsule (SQV-SGC) in combination with other antiretroviral agents: Multicenter study NV15182: 24 week analysis
23. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients
24. Improved survival and reduced progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine
25. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine
26. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study)
27. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleo-side analogues
28. Fortovase BID regimens in HIV-1 infected patients: Combination with 2 nucleoside analogs or with nelfinavir plus 1 NA
29. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism
30. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man
31. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
32. The Danish Protease Inhibitor Study: A randomized study comparing the virologic efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus Type 1 infection
33. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
34. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir
35. TM (saquinavir) soft gel capsule in combination with low dose ritonavir
36. Efficacy and safety of b.i.d. and t.i.d regimens of nelfinavir + saquinavir + stavudine (d4T) + lamivudine (3TC) in HIV-infected women: 48 week results of the Women's First Study
37. Indinavir - Saquinavir single dose pharmacokinetic study
38. Antagonism between human immunodeficiency virus Type 1 protease inhibitors indinavir and saquinavir in vitro
39. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine
40. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus Type 1
41. Drug interaction study between saquinavir (SQV) and nevirapine (NVP)
42. Summary of pharmacokinetic drug interaction studies with efavirenz
43. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229
44. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
45. Baseline human immunodeficiency virus Type 1 phenotype, genotype and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel saquinavir in AIDS clinical trails Group Protocol 333
46. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations
47. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
48. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pre-treated HIV-infected patients
49. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
50. Ritonavir, saquinavir and nevirapine as a salvage regimen for indinavir or ritonavir resistance
51. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens
52. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy
53. Activity of the combination of nelfinavir and saquinavir after failure of prior protease inhibitor therapy
54. Development of a cervical fat pad following therapy with HIV-1 protease inhibitors
55. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
56. Severe hyperglycemia in an HIV clinic: Preexisting versus drug-associated diabetes mellitus
57. Hypertension (HTN) in HIV Patients with Metabolic Dysregulation
58. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS
59. Osteopenia in a Randomized, Multicenter Study of Protease Inhibitor (PI) Substitution in Patients with the Lipodystrophy Syndrome and Well-Controlled HIV Viremia
60. Avascular Necrosis In HIV + Patients A Potential Link To Protease Inhibitors
61. Severe premature coronary artery disease with protease inhibitory
62. Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy
63. HIV protease inhibitors and increased bleeding in hemophilia?
64. Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors
65. Pharmacokinetic interaction between saquinavir and cyclosporin
66. Rifabutin (RBT) reduces saquinavir (SAQ) plasma levels in HIV-infected patients
67. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
68. Nelfinavir mesylate (NFV) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HIV+ patients
69. Nelfinavir (NFV) increases plasma exposure of saquinavir in hard gel capsule (SQV-HGC) in HIV+ patients
70. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers
71. Itraconazole and HIV protease inhibitors: An important interaction
72. Agenerase in dual PI combination therapy with saquinavir, indinavir, or nelfinavir: Emergence of resistance
73. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
74. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors
75. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and γ-hydroxybutyrate
76. A pharmacokinetic (PK) study of intermittent rifabutin (RB) dosing with a combination of ritonavir (RT) and saquinavir (SQ) in HIV patients
77. Pharmacokinetics of the triple combination of saquinavir, ritonavir and efavirenz in HIV-Positive patients
78. Pharmacokinetics of saquinavir, zidovudine and zalcitabine in combination therapy